Compare Intuitive Surgical, Inc. (ISRG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Intuitive Surgical, Inc. trades at $354.73 (market cap $122.33B), while Regeneron Pharmaceuticals Inc trades at $673.34 (market cap $70.94B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ISRG | REGN | |
|---|---|---|
Market Cap | $122.33B | $70.94B |
Sector | Health | Health |
52-Week High | $592.85 | $812.27 |
52-Week Low | $345.42 | $542.52 |
Enterprise Value | $113.71B | $64.90B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $354.00, up 2.48% today, but remains near its 52-week low of $344.55. The stock faces technical bearish pressure despite strong Q2 2026 earnings beats, with revenue reaching $10.06B in 2025 and net income margin at 28.45%. Recent news highlights investor concerns over moderated U.S. procedure growth and a cautious 2026 outlook, driving the stock's recent decline.
The outlook balances robust fundamentals against near-term headwinds. Wall Street maintains a bullish consensus price target of $504.56, but risks include slowing procedure growth and insurance-related challenges. Long-term growth drivers like global da Vinci adoption and AI integration offer upside, though volatility may persist amid sentiment shifts.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
